Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease

H. Matthew Cohn, Maneesh Dave, Edward Vincent Loftus, Jr

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Ulcerative colitis and Crohn's disease are chronic inflammatory bowel diseases for which there are no cures. These diseases are immunopathogenic, and medical treatment is centered on the temperance of a dysregulated immune response to allow mucosal healing and prevent the sequelae of fistulation and stenosis. Accordingly, the armamentarium of medications, which has expanded immensely in recent history, is not without significant infectious and neoplastic risks. Many of these untoward effects can be mitigated by screening and avoidance of contraindicated medications. This review seeks to highlight the cautions for use of immunomodulators, anticytokine, and α4-integrin antagonists. The potential adverse events are further complicated by substantial heterogeneity in disease phenotype in the inflammatory bowel disease population. Large patient registries and databases provide considerable experience and knowledge to calculate the incidence of safety outcomes. To identify rarer outcomes after prolonged therapy, more prospective studies and continued adverse event reporting will aid safe application and minimize potential harms.

Original languageEnglish (US)
Pages (from-to)1301-1315
Number of pages15
JournalInflammatory Bowel Diseases
Volume23
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Biological Therapy
Immunologic Factors
Inflammatory Bowel Diseases
Temperance
Ulcerative Colitis
Integrins
Crohn Disease
Registries
Pathologic Constriction
History
Databases
Prospective Studies
Phenotype
Safety
Incidence
Therapeutics
Population

Keywords

  • adalimumab
  • azathioprine
  • certolizumab pegol
  • contraindications
  • Crohn's disease
  • golimumab
  • inflammatory bowel disease
  • infliximab
  • mercaptopurine
  • methotrexate
  • natalizumab
  • ulcerative colitis
  • ustekinumab
  • vedolizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. / Cohn, H. Matthew; Dave, Maneesh; Loftus, Jr, Edward Vincent.

In: Inflammatory Bowel Diseases, Vol. 23, No. 8, 01.08.2017, p. 1301-1315.

Research output: Contribution to journalReview article

@article{507cc432574e4835b53be7d26fea510b,
title = "Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease",
abstract = "Ulcerative colitis and Crohn's disease are chronic inflammatory bowel diseases for which there are no cures. These diseases are immunopathogenic, and medical treatment is centered on the temperance of a dysregulated immune response to allow mucosal healing and prevent the sequelae of fistulation and stenosis. Accordingly, the armamentarium of medications, which has expanded immensely in recent history, is not without significant infectious and neoplastic risks. Many of these untoward effects can be mitigated by screening and avoidance of contraindicated medications. This review seeks to highlight the cautions for use of immunomodulators, anticytokine, and α4-integrin antagonists. The potential adverse events are further complicated by substantial heterogeneity in disease phenotype in the inflammatory bowel disease population. Large patient registries and databases provide considerable experience and knowledge to calculate the incidence of safety outcomes. To identify rarer outcomes after prolonged therapy, more prospective studies and continued adverse event reporting will aid safe application and minimize potential harms.",
keywords = "adalimumab, azathioprine, certolizumab pegol, contraindications, Crohn's disease, golimumab, inflammatory bowel disease, infliximab, mercaptopurine, methotrexate, natalizumab, ulcerative colitis, ustekinumab, vedolizumab",
author = "Cohn, {H. Matthew} and Maneesh Dave and {Loftus, Jr}, {Edward Vincent}",
year = "2017",
month = "8",
day = "1",
doi = "10.1097/MIB.0000000000001199",
language = "English (US)",
volume = "23",
pages = "1301--1315",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease

AU - Cohn, H. Matthew

AU - Dave, Maneesh

AU - Loftus, Jr, Edward Vincent

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Ulcerative colitis and Crohn's disease are chronic inflammatory bowel diseases for which there are no cures. These diseases are immunopathogenic, and medical treatment is centered on the temperance of a dysregulated immune response to allow mucosal healing and prevent the sequelae of fistulation and stenosis. Accordingly, the armamentarium of medications, which has expanded immensely in recent history, is not without significant infectious and neoplastic risks. Many of these untoward effects can be mitigated by screening and avoidance of contraindicated medications. This review seeks to highlight the cautions for use of immunomodulators, anticytokine, and α4-integrin antagonists. The potential adverse events are further complicated by substantial heterogeneity in disease phenotype in the inflammatory bowel disease population. Large patient registries and databases provide considerable experience and knowledge to calculate the incidence of safety outcomes. To identify rarer outcomes after prolonged therapy, more prospective studies and continued adverse event reporting will aid safe application and minimize potential harms.

AB - Ulcerative colitis and Crohn's disease are chronic inflammatory bowel diseases for which there are no cures. These diseases are immunopathogenic, and medical treatment is centered on the temperance of a dysregulated immune response to allow mucosal healing and prevent the sequelae of fistulation and stenosis. Accordingly, the armamentarium of medications, which has expanded immensely in recent history, is not without significant infectious and neoplastic risks. Many of these untoward effects can be mitigated by screening and avoidance of contraindicated medications. This review seeks to highlight the cautions for use of immunomodulators, anticytokine, and α4-integrin antagonists. The potential adverse events are further complicated by substantial heterogeneity in disease phenotype in the inflammatory bowel disease population. Large patient registries and databases provide considerable experience and knowledge to calculate the incidence of safety outcomes. To identify rarer outcomes after prolonged therapy, more prospective studies and continued adverse event reporting will aid safe application and minimize potential harms.

KW - adalimumab

KW - azathioprine

KW - certolizumab pegol

KW - contraindications

KW - Crohn's disease

KW - golimumab

KW - inflammatory bowel disease

KW - infliximab

KW - mercaptopurine

KW - methotrexate

KW - natalizumab

KW - ulcerative colitis

KW - ustekinumab

KW - vedolizumab

UR - http://www.scopus.com/inward/record.url?scp=85026488948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026488948&partnerID=8YFLogxK

U2 - 10.1097/MIB.0000000000001199

DO - 10.1097/MIB.0000000000001199

M3 - Review article

C2 - 28708806

AN - SCOPUS:85026488948

VL - 23

SP - 1301

EP - 1315

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 8

ER -